NCT00566527View on ClinicalTrials.gov

Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,620

Participants

Timeline

Start Date

November 29, 2007

Primary Completion Date

December 29, 2008

Study Completion Date

December 29, 2008

Conditions

MeaslesMumpsRubellaVaricella

Interventions

BIOLOGICAL

ProQuad® manufactured with recombinant Human Albumin (rHA)

A 2-dose regimen of ProQuad® (0.5 mL per dose) given via subcutaneous injection into the deltoid muscle at a 3-month interval. Each dose contains measles virus Enders' Edmonston strain (live attenuated), mumps virus Jeryl Lynn™ (Level B) strain (live attenuated), rubella virus Wistar RA 27 or 3 strain (live attenuated), and varicella virus Oka or Merck strain (live attenuated).

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00566527 - Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) | Biotech Hunter | Biotech Hunter